许华曦博士，国家首批“千人计划” 国家级特聘专家，厦门市特聘专家，2010年入选福建省引进高层次创业创新人才，厦门大学生物医学研究院教授、博导、前任院长，福建省神经退
/>行性疾病及衰老研究重点实验室主任。曾任美国著名的洛克菲勒大学助理教授和以科研影响力（论文被应用次数）排名世界前列的Sanford-Burnham医学研究所的教授、神经退化性疾病Program（系）主任。 1981至1985年就读于厦门大学生物系生物化学专业。1985年毕业于厦门大学生物系生化专业，1988至1993年就读于美国爱因斯坦医学院，在Dennis Shields教授和Gunter Blobel教授（1999年诺贝尔医学奖得主）共同指导下从事激素原处理修饰及细胞内蛋白质运输的研究工作，证实了高尔基体反端扁囊（TGN）是激素原翻译后修饰的主要场所。1993年获博士学位并开始博士后研究，1994年起师从美国著名分子神经生物学专家Paul Greengard教授（2000年诺贝尔医学奖得主），从事分子神经生物学尤其是神经信号传导、记忆及衰老方面的研究。
许华曦教授多年从事老年痴呆症的分子及细胞生物学的研究工作，是国际上老年痴呆症研究的权威专家之一，曾主持多项美国NIH项目（4项R01及1项PPG子项目，总金额上千万美元）。他先后在多种国际一流学术杂志（如:自然医学、自然结构及分子生物学、神经元、细胞生物学杂志、美国科学院院刊、神经科学杂志等）上发表论文70多篇（大多数为第一或通讯作者）。其论文总影响因子高达500多，论文被引用四千多次。荣获包括Ellison杰出青年奖、 Ruth Salta青年成就奖、Zenith Fellow（协会顶尖会员）奖在内的多项科研奖励。他还多次被美国和国际学术会议以及70多所大学研究机构邀请做学术报告或担任大会主席。他现为NIH基金评审(Study Section, CDIN组)的正式成员和 (ICI组、老年痴呆症的药开发SEP组及两个Program Project Grant组)特邀评审；他还先后为世界多个基金委员会评审科研基金及为几十家科学杂志审稿和撰写综述文章。2006年创办并担任 “Molecular Neurodegeneration” 杂志（SCI影响因子为5.091）的（共同）主编。同时担任三家生物医药公司的科学顾问；拥有三项美国专利。2001年受聘为同济医科大学客座教授，清华大学生命科学技术系客座教授；2002年受聘为厦门大学特聘教授。2003 年受聘为中南大学湘雅医学院客座教授；荣获中国国家杰出(海外)青年基金奖；2010受聘为加州大学圣地亚哥分校客座教授。
个人英文简介
Huaxi Xu, Ph.D received his Ph.D. degree in 1993 in the areas of prohormone processing and vesicle biogenesis and sorting in the trans Golgi Network, from Albert Einstein College of Medicine under the supervision of Professor Dennis Shields and was co supervised by Professor Gunter Blobel (1999 Nobel Laureate in Physiology & Medicine). Dr. Xu conducted his postdoctoral research from 1994 to 1998 in the area of neural signal transduction in the laboratory of Paul Greengard (2000 Nobel Laureate in Physiology & Medicine) at The Rockefeller University. He was appointed assistant professor at The Rockefeller University in 1998; and associate professor in 2003 then full professor and program director in 2008 at The Burnham Institute (now Sanford Burnham Medical Research Institute) these two prestigious institutes rank among the top 15 leaders in scientific impact on research worldwide.
Dr. Xu's research focuses on understanding the molecular events that underlie the pathogenesis of Alzheimer's disease (AD), which integrates genetic, neurobiologic, molecular and cellular information to clarify the normal biology of beta amyloid precursor protein and presenilins and the mechanisms by which mutant genes that alter these proteins cause AD. These research projects investigate the proteolytic processing and trafficking of beta amyloid protein, the abnormal phosphorylation of tau, and also attempt to discover novel genes and genetic pathways that affect beta amyloid processing. The goal is to characterize the cellular and molecular cascade of early events that lead to the etiopathogenesis of AD, and uncover information critical for the development of rational therapeutic strategies for the treatment of this devastating disorder.
Over the last decade, Dr. Xu has become an internationally recognized scientist in the field of Alzheimer research and has made significant contributions to molecular and cellular neuroscience. His work has been presented at numerous scientific conferences and at more than 70 universities or institutes (e.g., Harvard and Columbia Univ. etc.) worldwide where he has been symposium chair or an invited speaker. Dr. Xu's research has given rise to more than 70 publications in world's top medical research journals (such as Nature Medicine, Neuron, Proceedings of National Academy of Sciences etc.) with a total impact factor of over 550. His research publications (mostly as either first or correspondent author) have been cited nearly 5,000 times. Dr. Xu's research has been funded by the US government the NIH (including four R01 grants and one P01 project, totaling over 10 million dollars), the Alzheimer's Association, the American Health Assistance Foundation, the American Federation for Aging Research, and the Ellison Medical Foundation. He has reviewed or edited numerous manuscripts for a variety of high impact journals, and served as either a regular or an ad hoc member of many NIH study sections. Dr. Xu cofounded and serve as Co Editor in Chief of "Molecular Neurodegeneration",a journal with the SCI impact factor of 5.4. Dr. Xu has received many prestigious awards such as The Ruth Salta Junior Investigator Achievement Award, Ellison New Scholars in Aging Award and Alzheimer's Association's Zenith Fellow Award. He is also a recipient of China's Qian Ren Plan as an inaugural selection and National Fund for Distinguished Young Scholars (Type B, in 2003). The discoveries and breakthroughs made from Dr. Xu's research group over the last decade have attracted much public attention and broadcasted by main stream media such as CNN, NBC, ABC, New York Times, New York Newsday, Sciencentral and Yahoo etc.
代表性成果 论文发表：
(1) The Rps23rg gene family originated through retroposition of the ribosomal protein s23 mRNA and encodes proteins that decrease Alzheimer’s b-amyloid level and tau phosphorylation，Hum Mol Genet ，2010年10月
(2) Substrate check of gamma-secretase，Nat Struct Mol Biol，2010年02月
(3) A Functional Mouse Retroposed Gene Rps23r1 Reduces Alzheimer’s β-Amyloid Levels and Tau Phosphorylation，Neuron，2009年11月
(4) Presenilin/gamma-secretase-dependent processing of APP regulates EGFR expression. ，Proc. Natl. Acad. Sci. ，2007年04月
(5) Hypoxia inducible factor 1 (HIF-1a)-mediated hypoxia increases BACE1 expression and β-amyloid generation，J. Biol. Chem，2007年04月
(6) Transcriptional regulation of APH-1A and increased -secretase cleavage of APP and Notch by HIF-1 and hypoxia，FASEB J，2006年06月
(7) Transcriptional regulation of PEN-2, a key component of the g-secretase complex, by CREB，Mol Cell Biol.，2006年03月
(8) Phospholipase D1 corrects impaired APP trafficking and neurite outgrowth in familial Alzheimer’s disease-linked presenilin-1 mutant neurons. ，Proc. Natl. Acad. Sci. ，2006年02月
(9) Potential Roles of Insulin and IGF-1 in Alzheimer's Disease，Trends in Neurosciences，2003年10月
(10) Chaperones increase association of tau protein with microtubules.，Proc Natl Acad Sci ，2003年01月
(11) Does Insulin Dysfunction Play a Role in Alzheimer's Disease?，Trends in Pharmacological Sciences，2002年10月
(12) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761.，Proc Natl Acad Sci，2002年09月
(13) Does Insulin Dysfunction Play a Role in Alzheimer's Disease， Trends in Pharmacological Sciences，2002年06月
(14) Testosterone Reduces Neuronal Secretion of Alzheimer ß-amyloid Peptides，Proc. Natl. Acad. Sci. USA，2000年02月
(15) Endoplasmic Reticulum and trans-Golgi Network Generate Distinct Populations of Alzheimer ß-Amyloid Peptides，Proc. Natl. Acad. Sci，1999年02月
(16) Estrogen Reduces Neuronal Generation of Alzheimer ß-amyloid Peptides，Nature Medicine，1998年05月
(17) Generation of Alzheimer ß-amyloid Protein in the trans-Golgi Network in the Apparent Absence of Vesicle Formation.，Proc. Natl. Acad. Sci. USA.，1997年04月
(18) Metabolism of Alzheimer ß-Amyloid Precursor Protein: Regulation by Protein Kinase A in Intact Cells and in a Cell-Free System，Proc. Natl. Acad. Sci. USA.，1996年04月
(19) Prohormone processing in the trans-Golgi network: endoproteolytic cleavage of prosomatostatin and formation of nascent secretory vesicles in permeabilized cells.，J Cell Biol，1993年09月
专著发表：
(1) 分子细胞生物学，清华大学出版社，2006年09月，教材
(2) Amyloid Precursor Protein: A Practical Approach，CRC Press，2004年12月，学术专著
获奖、专利和发明：
(1) Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders，发明专利，2004年02月，USPTO，等级：1
(2) Appoptosin and uses thereof for treating neurodegenerative disease and cancer，发明专利，2007年12月，USPTO，等级：1
(3) Compositions and methods for inhibiting gsk3 activity and uses thereof，发明专利，2009年09月，USPTO，等级：1
(4) 青年学者奖，其他科研奖，2002年01月，American Federation for Aging Research，等级：1
(5) 中国国家杰出(海外)青年基金奖，其他科研奖，2003年01月，国家自然科学基金委员会，等级：1
(6) Ruth Salta青年成就奖，其他科研奖，2003年01月，American Health Assistance Foundation，等级：1
(7) Ellison学者奖，其他科研奖，2003年01月，Ellison Medical Foundation，等级：1
(8) Zenith Fellow奖，其他科研奖，2007年01月，Alzheimer’s Association，等级：1
